Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Liver Diseases Therapeutics Market 2015-2019

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 95 | Code: MRS - 35089


Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

The analysts forecast global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.

Based on disease indication, the market is segmented as follows:

  • Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
  • Liver cirrhosis
  • Liver cancer
  • Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:

  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.

The report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Other prominent vendors

  • AbbVie
  • Achillion Pharmaceuticals
  • Advinus
  • Angion Biomedica
  • AstraZeneca
  • Bayer
  • BiOrion
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celsion
  • Conatus
  • Digna Biotech
  • Dynavax Technologies
  • Eli Lilly
  • Galectin Therapeutics
  • Genfit
  • GenKyoTex
  • Isis Pharmaceuticals
  • Janssen Pharmaceuticals
  • Kaketsuken
  • La Jolla Pharmaceutical
  • LG Life Sciences
  • Mitsubishi Tanabe Pharma
  • Nitto Denko
  • Novartis
  • Onyx Pharmaceuticals
  • Phenex Pharmaceuticals
  • Promedior
  • Promethera Biosciences
  • ProMetic Life Sciences
  • Raptor Pharmaceuticals
  • Shenzhen Kangtai Biological Products
  • TCM Biotech
  • Tobira Therapeutics
  • VBL Therapeutics
  • Verva Pharmaceuticals
  • Virobay
  • Zafgen

Key market driver

  • Increased prevalence of liver diseases
  • For a full, detailed list, view our report

Key market challenge

  • Multiple patent expiries
  • For a full, detailed list, view our report

Key market trend

  • Growing public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors


Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Hepatitis
Liver cancer
Liver cirrhosis
Nonalcoholic fatty liver disease

PART 06: Market landscape
Global liver diseases therapeutics market

PART 07: Market segmentation by disease
Hepatitis
Liver cirrhosis
Liver cancer
Nonalcoholic fatty liver disease

PART 08: Global hepatitis therapeutics market
Global hepatitis A therapeutics market
Global hepatitis B therapeutics market
Global hepatitis C therapeutics market

PART 09: Global liver cancer therapeutics market

PART 10: Global nonalcoholic fatty liver disease therapeutics market

PART 11: Global liver cirrhosis therapeutics market

PART 12: Market segmentation by type of molecule
Biologics
Small molecules

PART 13: Geographical segmentation
Liver diseases therapeutics market in Americas
Liver diseases therapeutics market in EMEA
Liver diseases therapeutics market in APAC

PART 14: Market drivers

PART 15: Impact of drivers

PART 16: Market challenges

PART 17: Impact of drivers and challenges

PART 18: Market trends

PART 19: Vendor landscape
Competitive scenario
Market share analysis 2014
Other and future prominent vendors

PART 20: Key vendor analysis
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck

PART 21: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Hepatitis: Mode of transmission and incubation period
Exhibit 03: Various modes of transmission of hepatitis B viral infection
Exhibit 04: Various modes of transmission of hepatitis C viral infection
Exhibit 05: Worldwide endemicity of hepatitis A virus infection
Exhibit 06: Worldwide endemicity of hepatitis B virus infection
Exhibit 07: Prevalence of hepatitis B in US 2005-2013
Exhibit 08: Prevalence of hepatitis C across regions
Exhibit 09: Antibodies indicating hepatitis
Exhibit 10: Tests for viral proteins and genetic material
Exhibit 11: Screening tests for hepatitis C infection
Exhibit 12: Recommended dosages and schedules of hepatitis A vaccines
Exhibit 13: Global liver diseases therapeutics market 2014-2019 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global liver diseases therapeutics market by disease 2014
Exhibit 16: Global hepatitis therapeutics market 2014-2019 ($ millions)
Exhibit 17: Global hepatitis A therapeutics market 2014-2019 ($ millions)
Exhibit 18: Global hepatitis B therapeutics market 2014-2019 ($ millions)
Exhibit 19: Global hepatitis C therapeutics market 2014-2019 ($ millions)
Exhibit 20: Global hepatitis therapeutics market by type 2014
Exhibit 21: Global liver cancer therapeutics market 2014-2019 ($ millions)
Exhibit 22: Global liver cancer therapeutics market: Challenges and drivers
Exhibit 23: Global nonalcoholic fatty liver disease therapeutics market 2014-2019 ($ millions)
Exhibit 24: Global nonalcoholic fatty liver disease therapeutics market: Challenges and drivers
Exhibit 25: Global liver cirrhosis therapeutics market 2014-2019 ($ millions)
Exhibit 26: Global liver cirrhosis therapeutics market: Challenges and drivers
Exhibit 27: Global liver diseases therapeutics market by geography 2014
Exhibit 28: Liver diseases therapeutics market in Americas ($ billions)
Exhibit 29: Liver diseases therapeutics market in EMEA ($ billions)
Exhibit 30: Liver diseases therapeutics market in APAC ($ billions)
Exhibit 31: Impact of drivers
Exhibit 32: Impact of drivers and challenges
Exhibit 33: Johnson & Johnson: Business segmentation

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)2500 View Pricing